Licenses and Royalties. (a) Keep each material License affecting any Collateral (including the manufacture, distribution or disposition of Inventory) or any other material Property of Obligors and Subsidiaries in full force and effect (provided, that any Obligor may allow any License to terminate in accordance with its terms if such Obligor has provided prior written notice to Agent of such termination and after the termination of any “sell-off” period allowed under such terminated License (or if no such period exists, upon the termination of the License), such Obligor owns no more than an aggregate amount of $250,000 of Inventory (determined based on cost) which is impacted by such License); promptly notify Agent of any material proposed material modification to any such License, or entry into any new material License, in each case at least 30 days prior to its effective date; and notify Agent of any material default or material breach asserted by any Person to have occurred under any material License;
Licenses and Royalties. Client shall obtain all necessary licenses and pay all royalties, fees, fines, and/or penalties required to be paid by law or by any contractual arrangements with respect to the presentation of the Event. Client warrants and represents that all copyrighted materials to be presented at the University during the Event have been or will be duly licensed and authorized.
Licenses and Royalties. (a) Keep each Material License in full force and effect; promptly notify Agent of any proposed modification to any such Material License, or entry into any new Material License, in each case at least 10 days prior to its effective date; and notify Agent of any default or breach asserted by any Person to have occurred under any such Material License;
Licenses and Royalties. Except as set forth on Schedule 5.16 hereto, neither Quantime nor Subsidiary is a licensee under any license, including, without limitation, licenses with respect to source codes used or to be used in either Quantime's or Subsidiary's software products, and neither has an obligation to pay royalties to any third party in connection therewith. Neither Quantime nor Subsidiary has granted to any individual or entity any rights or security interests with respect to the source codes for either Quantime's or Subsidiary's software products. Quantime has not breached in any material respect and has not caused to exist a material default under any such licenses and, to the best of the Quantime Insiders' knowledge, there is no basis for any valid claim or default in any respect under such licenses and no other party is in breach or default thereof.
Licenses and Royalties. 8.1. Subject to the terms of this Agreement, (i) Spectra hereby grants to Customer a worldwide right and license, with rights to sublicense only in connection with Customer Products, under the Spectra System Technology to make, have made, use and sell Customer Products in Customer's Field an d Customer's Exclusive Field, and (ii) Customer hereby grants to Spectra a worldwide right and license, with rights to sublicense only in connection with Spectra products, under Customer Program Technology to make, have made, use and sell Spectra Products for resale outside of Customer's Exclusive Field. Except as set forth in Section 8.5 and 8.6, the license granted Customer herein expressly excludes the right to manufacture Printheads or Inks.
Licenses and Royalties. Except as set forth on SCHEDULE 2.12 hereto, DeltaPoint is not a licensee under any license with respect to the Assets, including, without limitation, licenses with respect to source codes used or to be used in DeltaGraph, and does not have an obligation to pay royalties to any third party in connection therewith, and DeltaPoint has not granted to any individual or entity any rights with respect to the source codes for DeltaGraph. Notwithstanding anything to the contrary contained herein, DeltaPoint has paid any and all royalties due through the Effective Date under such licenses and, with respect to that certain Software Publishing Agreement dated as of June 30, 1992, as same may have been amended, between DeltaPoint and Halcyon Software, Inc. (the "Halcyon Agreement"), no royalty is due or applicable to DeltaGraph. No royalties are due or payable with respect to DeltaGraph under that certain Small Developer Porting Technology License Agreement dated as of June 7, 1994 between DeltaPoint and Altura Software, Inc.
Licenses and Royalties. DataStat is not a licensee under any license with respect to the Assets, including, without limitation, licenses with respect to source codes used or to be used in VStat, and does not have an obligation to pay royalties to any third party in connection therewith, and DataStat has not granted to any individual or entity any rights with respect to the source codes for VStat.
Licenses and Royalties. 5.1 With regard to Catalysts, Sorbents and Fuel Processors which are the subject of jointly owned Project Patent Properties and jointly developed Technical Information, for a period of three (3) years from December 31, 2001: (i) Engelhard shall have a royalty-free exclusive right and license, with right to sublicense, to manufacture, have manufactured, use and sell Catalysts and Sorbents; and (ii) HBT shall have a royalty-free exclusive right and license, with right to sublicense to manufacture, have manufactured, use and sell Fuel Processors and components thereof.
Licenses and Royalties. If Micromet decides to continue the development or Commercialization of a Collaboration Product pursuant to this Section 6.1, Micromet will bear all costs and expenses incurred by it in the development and Commercialization of such Collaboration Product, including any Technology Acquisition Payments becoming due and payable after Micromet has provided the Continuation Notice. In addition, Micromet will pay to MedImmune a [***] of such Collaboration Product that is equal to [***], subject to the [***] set forth in Section [***]. Payment of said royalty to MedImmune will expire if and when the [***] has reached the [***] in connection with the development of *** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. such Collaboration Product pursuant to the applicable Research Plan and Development Plan to the extent such [***] were not [***] under this Agreement, plus an interest charge of [***]% compounded annually on [***]. For the avoidance of doubt, notwithstanding the termination of royalty payments, Micromet will continue to pay all Technology Acquisition Payments under Technology Acquisition Agreements of MedImmune and Micromet that become due as a result of Micromet’s development and Commercialization of such Collaboration Products.
Licenses and Royalties. 3.1.1 Aurora hereby grants to Packard and its Affiliates ***.
